Researchers in the US have found that most people with early Alzheimer's disease are not following guidelines for promoting brain health, even if they are being prescribed anti-amyloid therapies. There was no significant difference between those taking Eisai and Biogen's anti-amyloid therapy Leqembi (lecanemab) and those not taking the drug, which was a surprising result. Among patients pursuing anti-amyloid therapy, more than 25% were not optimally adhering to 11 of the 15 studied brain health recommendations, and more than 50% were not optimally adhering to four of the recommendations, which was much the same as the untreated group. “While tools such as Brain Health Vital Signs can help patients and their providers better understand what they are doing well and where they can improve, it’s clear that structured, sustainable interventions are also necessary." Preliminary results suggest the approach can improve adherence to recommended brain health behaviours.